APP and Alzheimer disease: To validate these DEG changes in VUF6002‐treated young AD mice, quantitative polymerase chain reaction (qPCR) analysis of these 6 upregulated and top 20 downregulated DEGs (ranked by adjusted p‐value) was performed in the hippocampus of 8 months old APP/PS1 mice treated with VUF6002 for one month, during the same period as the behavior testing described above in Figure S7B (Supporting Information).